PAVmed Inc. is a medical device company. Its diversified pipeline of products address unmet clinical needs, which consists of CarpX (TM) to treat carpal tunnel syndrome; NextFlo(TM) and NextCath(TM) a disposable infusion pump; PortIO(TM) and NextCath interventional radiology and Caldus (TM) tissue ablation and cardiovascular intervention. PAVmed Inc. is headquartered in New York City.
| Revenue (Most Recent Fiscal Year) | $2.99M |
| Net Income (Most Recent Fiscal Year) | $39.79M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 10.06 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.67 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 6681.57% |
| Net Margin (Trailing 12 Months) | 7144.80% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -20.96% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.52 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.52 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1004.67 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.16 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.06 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.99 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.16 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 21.93M |
| Free Float | 20.33M |
| Market Capitalization | $10.27M |
| Average Volume (Last 20 Days) | 0.34M |
| Beta (Past 60 Months) | 1.08 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 19.93% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |